Literature DB >> 9892881

The monoethylglycinexylidide test for grading of liver cirrhosis.

L Fabris1, R M Jemmolo, G Toffolo, D Paleari, S Viaggi, M Rigon, F Casagrande, F Lirussi, M Strazzabosco, C Cobelli, L Okolicsanyi.   

Abstract

BACKGROUND: Monoethylglycinexylidide (MEGX) formation following lignocaine injection has recently been proposed as a simple dynamic liver function test based on a single measurement of its serum concentration. AIM: To determine the optimal sampling time for MEGX determination.
METHODS: A modelling analysis of lignocaine and MEGX kinetics was performed in seven normals and in four patients with compensated liver cirrhosis; a similar study was performed in 74 cirrhotic patients, divided into two groups according to disease severity (Pugh score).
RESULTS: Only the MEGX fractional formation rate (kf) and formation delay (tau) were significantly altered in cirrhotic patients compared to normals: kf = 0.15 +/- 0.03 vs. 0.32 +/- 0.10 min-1 (mean +/- s.d.); tau = 7.7 +/- 2.0 vs. 3.9 +/- 2.9 min-1. A good correlation was found between kf and late (r = 0.82) but not early (r = 0.63) serum MEGX formation, suggesting that late measurements for the clinical MEGX test are preferred. In the second part of our investigation, by discriminant analysis of MEGX test data for 74 cirrhotic patients, the late MEGX concentrations gave the best discrimination between the two classes. In particular, the 60 min MEGX concentration showed the best diagnostic accuracy (81%), sensitivity (75%) and specificity (84%). The association of this with other MEGX parameters, either singly or derived from the whole curve measurements, did not improve the performance of the method.
CONCLUSION: The MEGX test, based on a single determination 60 min after lignocaine injection, may be regarded as a simple and sensitive quantitative liver function test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892881     DOI: 10.1046/j.1365-2036.1999.00431.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.

Authors:  F Botta; E Giannini; P Romagnoli; A Fasoli; F Malfatti; B Chiarbonello; E Testa; D Risso; G Colla; R Testa
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.

Authors:  J Wojcicki; K Kozlowski; M Drozdzik; M Wojcicki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

Review 3.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.